Results 81 to 90 of about 51,359 (234)

Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine [PDF]

, 2019
Type 2 diabetes mellitus (T2DM) is a chronic disease that has reached the levels of a global epidemic. In order to achieve optimal glucose control, it is often necessary to rely on combination therapy of multiple drugs or insulin because uncontrolled ...
Andreozzi, F, Mannino, Gc, Sesti, G
core   +1 more source

Circulating Profiles of the Bile Acid Metabolomics in Patients With Polycystic Ovary Syndrome Treated With Metformin or Canagliflozin

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 2, February 2026.
ABSTRACT Objective Bile acids are indispensable modulators in the development of polycystic ovary syndrome (PCOS). Our previous study identified that metformin and canagliflozin have similar efficacy in patients with PCOS combined with insulin resistance (IR).
Qi Yan, Meili Cai, Nan Wang, Wenhao Wu, Hua Zhang, Yikun Zhu, Jing Luo, Manna Zhang, Jin Li   +8 more
wiley   +1 more source

Association of high-sensitive C-reactive protein with advanced stage beta-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus [PDF]

, 2006
Background: Type 2 diabetes mellitus is associated with increased cardiovascular risk. One laboratory marker for cardiovascular risk assessment is high-sensitivity C-reactive protein (hsCRP).
Balkau, Forst, Haffner, Haffner, Hedblad, Howard, Huupponen, Langenfeld, Maseri, Matthews, Morrow, Nissen, Paice, Pfützner, Pfützner, Pfützner, Pfützner, Pfützner, Pfützner, Pfützner, Ridker, Ridker, Ridker, Ridker, Ridker, Ridker, Riveline, Ross, Saito, Sellmayer, Serrano Rios, Simpson, Willerson, Yudkin   +33 more
core   +1 more source

Model‐Based Meta‐Analysis of the Relationship Between Pioglitazone and Histological Outcomes in Metabolic Dysfunction‐Associated Steatohepatitis Patients

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Given the high prevalence of the population who have metabolic dysfunction‐associated steatohepatitis (MASH), interest is growing in MASH‐targeted treatments. However, currently, there has been only one regulatory approved drug for MASH (Rezdiffra).
Quyen Thi Tran, Tham Thi Bui, Lien Thi Ngo, Bo Ram Yang, In‐Hwan Baek, Van Hung Nguyen, Kyung Ae Lee, Hwi‐yeol Yun, Jung‐woo Chae, Soyoung Lee, Jae Hyun Kim, Woojin Jung   +11 more
wiley   +1 more source

A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population

Indian Journal of Endocrinology and Metabolism, 2014
Objectives: This retrospective cohort study analyzed the clinical data of cancer patients conducted in a cancer hospital, Chennai to assess the correlation (if any) between use of antidiabetic agents including pioglitazone and the incidence of bladder ...
V Balaji, V Seshiah, G Ashtalakshmi, S G Ramanan, M Janarthinakani   +4 more
doaj   +1 more source

Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia [PDF]

, 2011
OBJECTIVE: Lactic acidosis has been associated with use of metformin. Hypoglycemia is a major concern using sulfonylureas. The aim of this study was to compare the risk of lactic acidosis and hypoglycemia among patients with type 2 diabetes using oral ...
Bodmer, Michael, Jick, Susan S., Krähenbühl, Stephan, Meier, Christian, Meier, Christoph R.   +4 more
core   +2 more sources

Diabetes management in maternally inherited diabetes and deafness (MIDD): A review and a proposed treatment algorithm

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 826-839, February 2026.
Abstract Maternally inherited diabetes and deafness (MIDD) is a mitochondrial disorder usually caused by the variant m.3243A>G in the MT‐TL1 gene. We have proposed that diabetes in MIDD arises from a combination of insulin resistance and impaired β‐cell function that is more likely to occur in the presence of high skeletal muscle heteroplasmy and ...
Ahsen Chaudhry, David M. Thompson, Jean‐Pierre Chanoine   +2 more
wiley   +1 more source

Synergistic associations of metformin and GLP‐1 receptor agonist use with adiposity‐related cancer incidence in people living with type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 946-959, February 2026.
Abstract Background Metformin and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) may reduce the risk of adiposity‐related cancers in patients with type 2 diabetes (T2D). The potential synergistic effects of these treatments on cancer incidence remain unclear, considering their distinct biological mechanisms and their associated effects on body ...
Alex E. Henney, Megan Heague, David R. Riley, Theresa J. Hydes, Matthew Anson, Uazman Alam, Daniel J. Cuthbertson   +6 more
wiley   +1 more source

Heart matters: How glucose‐ and lipid‐modulating drugs remodel epicardial adipose tissue accumulation, inflammatory patterns and browning

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 878-894, February 2026.
Abstract Epicardial adipose tissue (EAT) is a metabolically active visceral fat depot located between the myocardium and the visceral pericardium, exerting direct paracrine and vasocrine effects on the heart and coronary vessels. Under physiological conditions, EAT supports myocardial energy metabolism and thermoregulation through fatty acid supply and
Elisabeth Heuboeck, Charnkamal Singh Bhogal, Markus Mandl   +2 more
wiley   +1 more source

P-537: Pioglitazone blunts the blood pressure response to angiotensin II in insulin-resistant zucker rats [PDF]

, 2017
Thiazolidinediones are high-affinity agonists of peroxisome proliferator-activated receptors (PPAR)-γ which have been found to lower blood pressure (BP) in animal models of diabetes and reno-vascular hypertension.
Brunner, Hans R., Burnier, Michel, Maillard, Marc, Nussberger, Juerg, Perregaux, Christine, Zanchi, Anne   +5 more
core